Navigation Links
Rheumatoid arthritis is a risk factor for cardiovascular disease
Date:6/13/2008

Paris, France, Friday 13 June 2008: The risk of cardiovascular disease (CVD) for people with rheumatoid arthritis (RA) has been found to be comparable to the risk of CVD in people with type 2 diabetes, according to the conclusions of two studies presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France.

At least one CV-event was reported in 8.6% of the RA population studied, a figure that was double that reported in the general population (4.3%), corresponding with an incidence of 3.14 per 100 patient/years (95% confidence interval (CI): 1.98-4.30) for RA patients, and 1.51 per 100 person/years (95%-CI: 1.18-1.84) for the general population.

In a second study, the age- and gender- adjusted prevalence odds ratios for CVD were found to be 2.3 (95%-CI: 1.3-4.0) for those with type 2 diabetes and 2.0 (95%-CI: 1.1-3.4) for those with RA, indicating a similar CVD risk for the two diseases.

Dr Mike Peters of the VU University Medical Center and Jan van Breemen Institute, Amsterdam, the Netherlands, an investigator in both studies (lead investigator: Dr Michael T Nurmohamed), said, "These two studies suggest that RA should be considered an important cardiovascular disease risk factor. Healthcare professionals treating those with the disease should therefore be aware of this elevated risk and advise their patients to follow a healthy diet and lifestyle and be alert to the early signs and symptoms of CVD in addition to managing their RA."

The studies both examined 353 randomly selected outpatients with RA (from the CARR study) and participants of a population-based cohort study on diabetes and CVD (the Hoorn study). The first study compared 3-year incident CVD in both the CARR and Hoorn studies, using Cox proportional hazards models. In the second, patients with normal fasting glucose levels from the CARR study (n=294) were compared to individuals from the Hoorn study with a norma
'/>"/>

Contact: Rory Berrie / Camilla Dormer
eularpressoffice@uk.cohnwolfe.com
44-077-892-70392
European League Against Rheumatism
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Novel DNA microarray chip predicts functional impairment and remission in rheumatoid arthritis
2. Early life infections increase the risk of rheumatoid arthritis and juvenile idiopathic arthritis
3. Rheumatoid arthritis factors equal to cardiovascular factors in risk of severe cardiovascular events
4. New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
5. HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
6. Hand bone mineral density is an effective predictor of mortality in rheumatoid arthritis
7. Biogen Idecs baminercept alfa shows promise in patients with rheumatoid arthritis
8. Golimumab Eases Rheumatoid Arthritis Symptoms
9. Researchers uncover higher prevalence of periodontal disease in rheumatoid arthritis patients
10. Drinking Cuts Rheumatoid Arthritis Risk
11. Regular tipple may curb risk of rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... Researchers have found that fecal transplantation is ... in immunocompromised patients. This is the result of a ... the Center for Women,s Gastrointestinal Medicine at The Women,s ... published online in advance of print in the ... , or C. diff , has increased to ...
(Date:7/9/2014)... July 9, 2014 There has been a ... UT Southwestern Medical Center using MyChart, the online, interactive ... results, communicate with their healthcare providers, schedule appointments, and ... of patients actively using MyChart each year ... year increased more than 10-fold, according to a study ...
(Date:7/9/2014)... Diseases (NIAID), part of the National Institutes of ... CRS3123, an investigational oral antibiotic intended to treat ... infection. CRS3123 (previously known as REP3123) is a ... sparing normal intestinal bacteria. , The Phase I ... and women ages 18 to 45 in a ...
(Date:7/9/2014)... , , , , , , , , ... , , , , , ... gunshot is a binaural recording using KEMAR, the weapon was an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm ... , , , , , ... , , , , , ...
(Date:7/8/2014)... Restoration has been awarded up to $15 million by ... four -year project aiming to help brain-injured people restore ... neurosurgery, engineering, neurobiology, psychology and physics will collaborate to ... the brain. , Memory is the process in which ... store it and retrieve it. Certain types of illnesses ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3
... 40th Annual Meeting on Women,s Cancer Proves Superiority of ... 11 New data presented on Saturday during the ... Annual Meeting on Women,s Cancer demonstrated the accuracy of ... test results and the Risk of Ovarian Malignancy Algorithm ...
... FY 2008 % change ... ------- -------- ------- ... +3.6%, Adjusted net income, excluding selected, items(1): ... Adjusted EPS excluding EUR5.49 +6.2% EUR1.25 ...
... Combination With Herceptin and Taxotere Will Become Decision ... a New Report from Decision ResourcesWALTHAM, Mass., Feb. ... leading research and advisory firms for pharmaceutical and ... approved in combination with emerging therapies, it will ...
... More Than 15% of Total RevenuesCHICAGO, Feb. 11 ... (OTC Bulletin Board: CGSY)), the world,s leading telecommunications ... its 2009 sales strategy will include a special ... vertical market, which represents more than 15% of ...
... to discuss recent findings showing that health-related ... and pharmacy costs-- Presentation includes real-world insights ... to develop integrated health and productivity enhancements ... and musculoskeletal disorders are significant cost drivers ...
... CLARA, Calif., Feb. 11 Samplify Systems, Inc., a ... today announced the selection of its SAM1600 family of ... real-time signal-compression technology, as a finalist in EDN ... The prestigious Innovation Awards honor the ...
Cached Medicine News:Health News:Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer 2Health News:Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer 3Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 2Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 3Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 4Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 5Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 6Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 7Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 8Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 9Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 10Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 11Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 12Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 13Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 14Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 15Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 16Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 17Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 18Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 19Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 20Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 21Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 22Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 23Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 24Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 25Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 26Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 27Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 28Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 29Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 30Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 31Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 32Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 33Health News:If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer 2
(Date:1/14/2014)... InformEx, North America,s leading business ... hold the 30 th edition of its annual conference ... from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... chemical and specialty chemical companies will take part in the ...
(Date:1/14/2014)... 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - ... instrumentation to place and insert the screw accurately - ... (e.g. ligament) repair or reconstruction as it holds the ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC ...
(Date:1/14/2014)... NineSigma , Inc., the leading innovation partner to ... , May 14-16, 2014 at the Global Center for ... This is the premier industry event ... through open innovation. Participants will learn how world-changing innovation ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... NEW YORK, Oct. 17, 2011 Levi & Korsinsky is ... or the "Company") (NASDAQ: ANDS ) for possible ... in connection with the sale of the Company to Roche ... will receive $3.70 in cash per share of Anadys stock ...
... 17, 2011 Verisk Health ... DxCG Risk Solutions suite to include greater predictive power ... International Classification of Diseases, Tenth Revision, ... includes new models that predict emergency department (ED) utilization and ...
Cached Medicine Technology:The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Anadys Pharmaceuticals Inc. in Connection with the Sale of the Company to Roche Holding AG 2Verisk Health's DxCG Risk Solutions Technology Ready to Support Industry Adoption of ICD-10-CM 2
Preclude Dura Substitute is the only non-biological membrane designed to "seal" around suture holes. 0.3 mm as nominal thickness....
... synthetic absorbable implant for the bridging of Dura ... is pliable, regardless of being used dry or ... must be taken, while implanting, to ensure that ... is oriented towards the cortex or the spinal ...
... is a non-absorbable dura ... purified polyesterurethane. Its microporous ... of fibroblast, supporting tissue ... minimizes suture channels, resulting ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Medicine Products: